Industry: Scientific research Region: UK Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
The company is a biotechnology enterprise focusing on the research and development of artificial intelligence aptamer drugs, which combines the ability of independent computing design with the closed-loop wet experiment discovery process to develop selective aptamer candidates for pharmaceutical and biotechnology enterprises. Its platform can be used for related protein families, disease-specific protein variants and challenging membrane protein targets. Aptamers are a kind of nucleic acid molecules that can bind to specific targets with high affinity, and have potential applications in the fields of medicine, diagnosis and targeted delivery. However, the traditional screening process still faces challenges in terms of the number of candidate molecules, the speed of research and development and the selectivity of complex targets. The company formed a closed-loop R&D system through artificial intelligence design and iterative verification of wet experiments. According to the information provided by the company, its platform can increase the number of candidate molecules by up to 300 times and the speed of discovery by up to 8 times. The company hopes to establish aptamer discovery cooperation with Asian pharmaceutical and biotechnology enterprises, form a business development pipeline in the Asia-Pacific region, and find a contract research organization that can undertake verification and transformation research, and at the same time understand local cooperation, intellectual property rights and contract arrangements.
Cooperation mode:
At present, the company is looking for a strategic partner in China, whose cooperation directions include aptamer drug discovery, target verification, transformation research, commissioned research and development, intellectual property cooperation and market expansion. The company hopes to establish cooperative relations with pharmaceutical enterprises, biotechnology enterprises, diagnostic enterprises, contract research organizations, scientific research institutions and industrial parks in China.